Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 10 2021
20 10 2021
Historique:
received:
07
06
2021
accepted:
24
09
2021
entrez:
21
10
2021
pubmed:
22
10
2021
medline:
28
1
2022
Statut:
epublish
Résumé
FLT3-ITD mutations are detected in approximately 25% of newly diagnosed adult acute myeloid leukemia (AML) patients and confer an adverse prognosis. The FLT3-ITD allelic ratio has clear prognostic value. Nevertheless, there are numerous manuscripts with contradictory results regarding the prognostic relevance of the length and insertion site (IS) of the FLT3-ITD fragment. We aimed to assess the prognostic impact of these variables on the complete remission (CR) rates, overall survival (OS) and relapse-free survival (RFS) of AML patients with FLT3-ITDmutations. We studied the FLT3-ITD length of 362 adult AML patients included in the PETHEMA AML registry. We tried to validate the thresholds of ITD length previously published (i.e., 39 bp and 70 bp) in intensively treated AML patients (n = 161). We also analyzed the mutational profile of 118 FLT3-ITD AML patients with an NGS panel of 39 genes and correlated mutational status with the length and IS of ITD. The AUC of the ROC curve of the ITD length for OS prediction was 0.504, and no differences were found when applying any of the thresholds for OS, RFS or CR rate. Only four out of 106 patients had ITD IS in the TKD1 domain. Our results, alongside previous publications, confirm that FLT3-ITD length lacks prognostic value and clinical applicability.
Identifiants
pubmed: 34671057
doi: 10.1038/s41598-021-00050-x
pii: 10.1038/s41598-021-00050-x
pmc: PMC8528825
doi:
Substances chimiques
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20745Informations de copyright
© 2021. The Author(s).
Références
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Leuk Lymphoma. 2018 Oct;59(10):2273-2286
pubmed: 29164965
Cancer Sci. 2018 Dec;109(12):3981-3992
pubmed: 30320942
Leuk Lymphoma. 2013 Jan;54(1):145-52
pubmed: 22721497
Leukemia. 2021 Jul 28;:
pubmed: 34316017
J Mol Diagn. 2003 May;5(2):96-102
pubmed: 12707374
Leukemia. 2013 Sep;27(9):1891-901
pubmed: 23783394
Blood Cancer J. 2015 Aug 14;5:e336
pubmed: 26832846
J Korean Med Sci. 2018 Jun 26;33(34):e213
pubmed: 30127705
Blood. 2009 Apr 23;113(17):4074-7
pubmed: 18483393
Blood. 2006 Jul 1;108(1):405-6; author reply 406
pubmed: 16790588
Blood. 2020 Jan 30;135(5):371-380
pubmed: 31826241
Ann Hematol. 2017 Dec;96(12):1993-2003
pubmed: 29090343
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Haematologica. 2020 Nov 12;Online ahead of print:
pubmed: 33179471
Blood Cancer J. 2020 May 4;10(5):48
pubmed: 32366841
Blood. 2014 Nov 27;124(23):3441-9
pubmed: 25270908
Hematology Am Soc Hematol Educ Program. 2013;2013:220-6
pubmed: 24319184
Blood. 2006 May 1;107(9):3724-6
pubmed: 16368883
Blood. 2008 Mar 1;111(5):2776-84
pubmed: 17957027
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957
pubmed: 28687581
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2009 Sep 17;114(12):2386-92
pubmed: 19602710
Genes Chromosomes Cancer. 2012 Oct;51(10):910-24
pubmed: 22674490
Haematologica. 2021 Aug 05;:
pubmed: 34348451
Blood. 2008 May 15;111(10):4930-3
pubmed: 18305215
Mol Clin Oncol. 2020 Aug;13(2):95-100
pubmed: 32714530
Haematologica. 2019 Jan;104(1):e9-e12
pubmed: 30076182
Blood. 2002 Jul 1;100(1):59-66
pubmed: 12070009
Blood. 2002 Jun 15;99(12):4326-35
pubmed: 12036858